Search Results
Your search for Jennifer Woyach, MD matches 8 pages
Showing 1 - 8
Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or...
Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic ...
Jennifer A. Woyach, MD, on CLL/SLL: 30-Month Follow-up and Subgroup Analysis of Pirtobrutinib
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma...
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with...
Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, talks about whether modifications of treatment based on minimal residual disease is beneficial to patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study
Jennifer Ann Woyach, MD, of The Ohio State University, discusses trial findings on ibrutinib alone or in combination with rituximab compared with bendamustine plus rituximab in untreated older people with chronic lymphocytic leukemia (Abstract 6).
ASH 2018: Ibrutinib Alone or in Combination With Rituximab vs Bendamustine Plus Rituximab in Older Patients With CLL
A new study presented by Woyach et al at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 6) showed that older patients with chronic lymphocytic leukemia (CLL) have a significantly lower rate of disease progression if treated with ibrutinib rather than...
Factors in Ibrutinib Discontinuation in Patients With Chronic Lymphocytic Leukemia
In a single-center study reported in JAMA Oncology, Maddocks et al found that Richter’s transformation accounted for early progression-related discontinuation of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and that CLL progression but not Richter’s...
